The FDA has approved a new drug called palopegteriparatide (Yorvipath) for the treatment of hypoparathyroidism in adults. This condition occurs when there are insufficient levels of parathyroid hormone, leading to complications such as neuromuscular irritability and kidney issues. The drug is designed to provide stable PTH levels over a 24-hour period, unlike traditional treatments that can cause fluctuations in calcium levels. Clinical trials showed that the drug was effective in normalizing serum calcium levels and reducing the need for conventional treatments. Common side effects include injection site reactions and vasodilatory symptoms. The drug is expected to be available in the US in the first quarter of 2025.
Source link
FDA OKs New Drug for Treating Hypoparathyroidism
